Back to Journals » Hepatic Medicine: Evidence and Research » Call For Papers

Hepatic Medicine: Evidence and Research


The following Article Collection/ Thematic Series is currently open for submissions:

Covid-19 and the liver

Dove Medical Press is pleased to invite you to submit your work to an upcoming Thematic Series on “Covid-19 (SARS-CoV-2) and the liver” edited by Editor-in-Chief Dr Gerond Lake-Bakaar in Hepatic Medicine: Evidence and Research.

When submitting your work, please use the promo code KQXEA, for 25% off the advertised article processing charge and to indicate that your manuscript should be considered for the Thematic Series on “Covid-19 and the Liver”. The deadline for submission of manuscripts is September 1st 2022.

For any enquiries, please email to Amanda Sleeth, Commissioning Editor, at [email protected]

About the Thematic Series

Liver damage has long been associated with COVID-19. Research has attributed several factors responsible for this damage; including a direct cytopathic attack from SARS-CoV-2, acute inflammatory damage, drug toxicity associated with therapy and severe hypoxia related to the pneumonia. Numerous mechanisms have been associated with the cytopathic effect, and much more is yet to be understood. The virus is present on the surface of endothelial cells and hepatocytes as well as cholangiocytes and the hyper-inflammatory reaction suggestive of HLH (hemophagocytic lymphohistiocytosis) has been associated with liver failure. Endothelial damage and coagulation dysfunction could trigger liver damage, and evidence shows that drugs used in the treatment of Covid have hepatotoxic potential.

Journal Editors are seeking original research, and review article submissions on the following topics:

• Innate immune signalling, SARS-CoV-2 and the liver
• Viral hepatology and SARS-CoV-2
• Transplant hepatology and SARS-CoV-2
• Mechanisms of liver injury due to SARS-CoV-2
• Mechanisms of liver failure due to SARS-CoV-2
• Direct pathogenic effects of SARS-CoV-2 on the liver
• Hepatotoxicity and drug therapy for SARS-CoV-2
• Cholangiopathies and SARS-CoV-2
• Improving outcomes in patients with liver dysfunction following SARS-CoV-2 infection
• Long Covid and the liver
• Long term impact of SARS-CoV-2 on the hepatitis patients
• Health related Quality of Life (HRQOL) in patients with chronic liver failure and SARS-CoV-2

View all papers in this thematic series


Call For Papers

Editor-in-Chief: Gerond V. Lake-Bakaar, MD

To see where Hepatic Medicine: Evidence and Research is indexed online view the Journal Metrics

What is the advantage to you of publishing in Hepatic Medicine: Evidence and Research?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Hepatic Medicine: Evidence and Research receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Hepatic Medicine: Evidence and Research has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution a publication processing fee.

PubMed Central
Hepatic Medicine: Evidence and Research is indexed on PubMed Central (title abbreviation: Hepat Med). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Gerond V. Lake-Bakaar
Editor-in-Chief
Hepatic Medicine: Evidence and Research

Email: Editor-in-Chief